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Background: In Taiwan, DNA-based newborn screening showed a surprisingly high incidence of a cardiac Fabry
mutation (IVS4 + 919G > A). The prevalence of this mutation is too high to be believed that it is a real pathogenic
mutation. The purpose of this study is to identify the cardiac pathologic characteristics in patients with left ventricular
hypertrophy and this mutation
Methods and results: Endomyocardial biopsies were obtained in 22 patients (Median age: 61, males: 17; females:
5) with left ventricular hypertrophy and the IVS4 + 919G > A mutation; five patients had not received enzyme
replacement therapy (ERT) before biopsy, while the other 17 patients had received ERT from 8 months to
51 months. Except for three patients who had received ERT for more than 3 years, all other patients showed
significant pathological change and globotriaosylceramide (Gb3) accumulation in their cardiomyocytes. In contrast
to classical Fabry patients, no Gb3 accumulation was found in the capillary endothelial cells of any of our patients.
Fourteen patients (63.6%) were found to have myofibrillolysis.
Conclusions: All of the untreated and most of the treated IVS4 + 919G > A patients showed typical pathological
changes of Fabry disease in their cardiomyocytes. No endothelial accumulation of Gb3 was found, which is similar
to the findings of several previous reports regarding later-onset Fabry disease. This result highly suggests that the
IVS4 + 919G > A is a real pathogenic later-onset Fabry mutation.
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hypertrophyBackground
Fabry disease (MIM 301500) is an X-linked lysosomal sto-
rage disorder resulting from deficient alpha-galactosidase A
(α-Gal A) activity. The estimated incidence of classic Fabry
disease is 1 in 40,000-60,000 males in the general popula-
tion [1]. The deficient α-Gal A activity results in progressive
accumulation of glycosphingolipid, predominantly globo-
triaosylceramide (Gb3), in the walls of small blood vessels,
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unless otherwise stated.epithelial cells, and cardiomyocytes. Clinical features in
classically affected patients include acroparesthesia, angio-
keratoma, and hypohidrosis in early childhood or adoles-
cence and progress to renal insufficiency, cardiomyopathy,
and cerebrovascular disease in adulthood [2-6]. Recently,
several different later-onset phenotypes of Fabry disease
have been identified, which have drawn the attention of
more physicians [7-9]. Patients with later-onset Fabry dis-
ease have higher residual enzyme activities than those of
the classical type. They lack the classic symptoms of Fabry
disease and present relatively fewer or isolated symptoms
such as hypertrophic cardiomyopathy, renal failure, or
cryptogenic stroke at later stages in life [10-14]. The
cardiac later-onset phenotype usually presents only with. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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opathy, mitral insufficiency and/or arrhythmias in the
fifth to eighth decade [12,15,16].
In Taiwan, our team first revealed a surprisingly high
incidence (approximately 1 in 1600 males) of a later-onset
GLA mutation, IVS4 + 919G >A (GenBank accession nos.
CS020811), in our population [17] and also identified this
mutation in a number of Taiwan Chinese adult patients
with idiopathic hypertrophic cardiomyopathy [18]. There-
after, another newborn screening center of Taiwan also re-
vealed a very similar incidence (1 in 1,460 males) of this
mutation in their study [19]. More recently, DNA-based
newborn screening for this mutation revealed a higher
incidence (1/875 in males and 1/399 in females) than
our previous enzyme-based Fabry newborn screening in
Taiwan [20]. Because of the high prevalence of this
IVS4 + 919G > A mutation in our population [21,22], we
analyzed the disease onset rate according to the ages of
the male and female adults with this mutation. 86 male
and 248 female adults who were older than 30 years
were enrolled in this analysis. We found the disease on-
set rate for both male and female patients increased
gradually with increasing age (Figure 1). Around 77% of
male adults and 35% of female adults, who were older
than 40 years old, had already developed hypertrophic
cardiomyopathy. In particular, 94%(32/34) of the males
who were older than 60 years old and 100% (6/6) who
were older than 70 years old showed significant hyper-
trophic cardiomyopathy (Figure 1). We believe this re-
sult strongly suggests that this IVS4 + 919G > A is a real
pathogenic mutation. Although, the IVS4 + 919G >A mu-
tation was found in such a high frequency, the pathologic
changes in later-onset Fabry disease with this specific mu-
tation is still poorly known. It is important to look intoFigure 1 Disease onset rate in male and female adults with IVS4 + 91
ages of male and female adults (>30y/o) with IVS4 + 919G > A mutation in
and the Y-axis showed the patient numbers. The disease onset rate increasthe pathologic characteristics and changes of cardiomyop-
athy in these patients [23].
Due to the high prevalence of IVS4 + 919G > A muta-
tion in our population, a new treatment guideline has
been set up by the Bureau of National Health Insur-
ance in Taiwan. All Fabry patients applying for enzyme
replacement therapy (ERT) funding from the national
health insurance have to receive an endomyocardial bi-
opsy examination to demonstrate that Fabry disease is
the primary cause of their hypertrophic cardiomyop-
athy. This guideline gives us the opportunity to ob-
serve a large series of cardiac pathologic changes in
these patients with left ventricular hypertrophy and the
IVS4 + 919G > A mutation.
Patients and methods
Patient population
A total of 22 Fabry patients (17 males and 5 females,
median age: 61 years old) with left ventricular hyper-
trophy carrying the IVS4 + 919G > A mutation were en-
rolled in this study. The demographic data, laboratory
results, image results and pathologic findings of the
endomyocardial biopsies were collected retrospectively
from December 2012 to April 2013.
Five patients (nos.1-5) did not receive ERT before endo-
myocardial biopsy. The others had received agalsidase alfa
(Replagal®, Shire) 0.2 mg/kg every other week as the en-
zyme replacement therapy for at least 8 months (range 8-
40 months). Two patients (nos. 16 and 17) had initially re-
ceived agalsidase beta (Fabrazyme®, Genzyme) 1 mg/kg
every other week and then changed to Replagal® 0.2 mg/kg
in 2009 owing to the global shortage of Fabrazyme.
The study complies with the Declaration of Helsinki
and is approved by the medical ethics committee of Taipei9G > A. The figure showed the disease onset rate according to the
males 1(A) and females 1(B). The X-axis showed the age distribution
ed gradually, as patients got older for both males and females.
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GLA gene mutation
Blood samples were obtained from these patients in blood
collecting tubes containing ethylene diamine tetraacetic
acid, and samples were stored at 4°C. DNA was isolated
from whole blood using the GFX genomic Blood DNA
Purification Kit (Amersham Biosciences, UK) following
the manufacturer’s instructions. The primer sets were
used to amplify the sequences of seven GLA exons and
the region including IVS4 + 919G > A [24,25]. The poly-
merase chain reaction products were analyzed by 1.5%
agarose I (Amresco) gel electrophoresis and then eluted
in the polymerase chain reaction Advanced PCR Clean
Up System (Viogene, USA.). Direct sequencing of the α-
Gal A gene was processed using the BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems) and
ABI Prism 3730 Sequencer [26].
Plasma α-Gal A activity and Plasma LysoGb3
Plasma α-Gal A activity was determined using the substrate
4-methylumbelliferyl α-D-galactopyranoside (5 mmol/L)
freshly prepared in 117 mmol/L N-acetyl-D-galactosamine/
50 mmol/L citric-phosphate buffer, pH 4.6, before every
assay. In brief, 50 μL of plasma was mixed with 300 μL
of the substrate solution, incubated at 37°C for 2 hours,
and 0.2 N glycine-NaOH was added to stop the reaction.
Fluorescence intensity was measured with the excitation
and emission wavelengths of 365 and 450 μm, respect-
ively [27,28]. Plasma LysoGb3 was detected by tandem
mass spectrometry that was performed in positive ion
mode (ES+) on a triple quadruple mass spectrometer
(Quattro Ultima, Waters, Milford, MA) with NeoLynx
software version 4.1. A multiple reaction monitoring
(MRM) mode was used for the measurement of lysoGb3.
The analyzing methods were modified from the protocol
provided by Shire [29].
Echocardiography
Echocardiography was performed routinely for the Fabry
patients to check the hypertrophic cardiomyopathy. Left
ventricular mass was calculated according to the Dever-
eux cube formula and indexed to height2.7 (LVMI). Left
ventricular hypertrophy by echocardiography was de-
fined by a LVMI of >47 g/m2.7 in women or >50 g/m2.7
in men [30-32]. To avoid variability of LMVI measure-
ments, only the results performed by two cardiologists
specializing in echocardiography and measured with the
same machine and protocol were used in this study.
Cardiac magnetic resonance imaging
Magnetic resonance imaging (MRI) of the heart was car-
ried out as part of stand assessment on a 1.5 T scanner(Excite II; GE medical systems, Milwaukee, WI). Late
enhancement (LE) technique by gadolinium-contrast
cardiac MRI examination was applied for the later-onset
Fabry patients for assessment of fibrosis. The partici-
pants underwent a scan with spin echo double IR
T1WI and T2WI pulse sequences and Fiesta pulse se-
quence, on axial, coronal, and variable scanning plans.
Images were acquired 10 minutes after the intravenous
injection of gadolinium. The myocardial delayed en-
hancement protocol included the pre-Gd axial FIESTA
cine and grid tagging in 8 mm slice, and the post-Gd
myocardial delayed enhancement of short axis/four-
chamber views in 8-mm slice and oblique axial cine of
ascending aorta in 8-mm slice to detect changes in tis-
sue integrity in the left ventricle myocardium [33-35].
Severe myocardial fibrosis was defined by at least two
affected left ventricular segments, which are followed
by the American heart association guideline [36], and
mild myocardial fibrosis was defined by one segment
affected.
Cardiac catheterization and endomyocardial biopsy
Right heart catheterization was approached via the right
internal jugular vein under digital X-ray guidance. A
flexible endomyocardial bioptome was inserted into the
right ventricle and 2-3 specimens were obtained from
interventricular septum and submitted to histological
examination.
Histological studies
Cardiac specimens selected for light microscope were
fixed in 10% buffered formalin, embedded in paraffin. The
sections were cut from the paraffin block and stained with
haematoxylin and eosin (H&E), and Masson’s trichrome.
Cardiac specimens selected for electron microscope were
fixed in 2.5% glutaraldehyde in phosphate buffer, post-
fixed with 1% OsO4 in Sorenson’s phosphate buffer,
followed by dehydration through a graded series of etha-
nol washes, and embedded in Spurr’s EPON. Semithin
sections were cut from the block and stained with tolui-
dine blue for adequate preview under a microscope. Ul-
trathin sections were prepared and examined under an
electron microscope.
In the idealized model of a cardiomyocyte, as an ellip-
tic cylinder, different diameters such as major axis (lon-
gest diameter) or minor axis (shortest diameter), etc. are
measured, even in one transverse section of a cardio-
myocyte. The current study revealed that, in the trans-
verse section, the ratio between the major axis and
minor axis of the cardiomyocytes is usually around 1.1
(11/10) [37]. Therefore, the diameters of cardiomyocytes
in transverse section can be approximately estimated.
Because the minor axis of the transverse section of car-
diomyocytes can be measured more easily and reliably
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of the minor axis of the transverse section of cardio-
myocytes was used to present the diameter of cardio-
myocytes in several previous reports [38-41]. In
accordance with these previous reports, we measured
the minor axis at the nuclear level in transverse
section to present the diameter of cardiomyocytes
of our patients in this study. A total of 15 cells from 3
micrographs were measured for each sample. Control
samples were retrospectively obtained from 8 ano-
nymous patients who were provided by the depart-
ment of pathology in our medical center. All the samples
were obtained during the electrophysiology study for
arrhythmia. None of these patients had any evidence
of hypertrophic cardiomyopathy. All the histopatho-
logic specimens were blindly reviewed by the same
pathologist.
Data analysis and statistics
The data in some parts of the study were analyzed with
descriptive statistics (mean, standard deviation). Due to
the small number of patients and the uncontrolled nature
of this study, no inferential statistics were used. Results
are presented as actual measurements from individual pa-
tients. SPSS Version 20 (SPSS Inc, Chicago, Illinois, USA)
was used for descriptive statistics.
Results
The demographic data and clinical manifestations of these
patients are shown in Table 1. Interestingly, high preva-
lences of hypertension and hyperlipidemia were noted in
these IVS4 + 919G > A patients with hypertrophic cardio-
myopathy. Out of these 22 patients, 12 (54.5%) were noted
to have hypertension. All of these hypertensive patients
received anti-hypertensive treatment and were kept
normotensive (<140/90 mmHg) for at least 6 months
before commencement of ERT. Seven (31.8%) patients
were found to have hyperlipidemia and all of them were
well controlled by medication for at least 6 months.
Twenty out of 22 patients received gadolinium-contrast
enhancement cardiac MRI with LE technique and 6 pa-
tients (30.0%) were found to have severe fibrosis which is
defined as at least 2 segments that are positive in myocar-
dium delayed enhancement scan.
All the endomyocardial biopsies were successfully per-
formed without complication. For the pathologic change
of the endomyocardial biopsies, all 22 patients (100%)
showed myocardial hypertrophic change with distorted
nuclei, and increased cardiomyocyte size with H&E
staining. Five (100%) of the patients who did not receive
ERT showed diffuse vacuolization in their myocardiocytes
(Figure 2A) which is a common pathologic finding for
Gb3 accumulation in cardiac biopsies of Fabry patients. In
the other 17 patients who had received ERT, except for 3patients (nos. 16, 17 and 22) who had received ERT for
more than 3 years (Figure 3), all of them also showed
diffuse Gb3 accumulation in cardiomyocytes. Regarding
the toluidine blue staining, except those 3 patients (nos.
16, 17 and 22), the other 19 patients were also noted to
have a lot of dark blue substance accumulation in cardi-
omyocytes, which is consistent with Gb3 accumulation
(Figure 2C and D). In addition to Gb3 accumulation, pa-
tient no. 10 was found to have interstitial fibrosis among
the cardiomyocytes with H&E staining (Figure 2B). Re-
garding the electron microscopic examination, except for
those three patients, all other patients were found to have
abundant lamellar myelin bodies in their cardiomyocytes
(Figure 4). Furthermore, 14 patients (63.6%) were found to
have significant myofibrillolysis (Figure 4D). There was no
Gb3 accumulation in the capillary endothelium of any of
these patients (Figure 4E, and F), which is compatible with
the histopathologic finding of later-onset Fabry disease.
The diameters of cardiomyocytes were measured in all
22 patients (Figure 5). The average diameter of the car-
diomyocytes was 25.35 ± 6.02 μm. The result of each in-
dividual is shown in Table 1. The average diameter of
the control cardiomyocytes was 14.89 ± 2.63 μm.
Discussion
Recently, the later-onset phenotypes of Fabry disease
were found to be about 10 times more frequent in most
populations [1,20,42,43]. Owing to the characteristics,
the terminology “later-onset” Fabry disease might be
more appropriate than “variant” Fabry disease. In fact,
an increasing number of novel mutations have been
found and believed to be later-onset mutations through
high-risk patient screenings or newborn screenings. On
the other hand, some mutations, which were previously
thought to be later-onset mutations, have been proved
to be non-pathogenic. The most noticeable example is
the p,E66Q mutation (c.196G > C), a previously identi-
fied renal later onset type mutation, which has a very
high prevalence rate in Japanese and Korean populations
(0.5-1%) and which has now been proved by pathologic
studies to be merely a single nucleotide polymorphism,
not a pathogenic mutation [44]. Therefore, it is insufficient
to confirm a later onset mutation based on its enzyme ac-
tivity and clinical manifestations such as hypertrophic car-
diomyopathy or renal impairment.
Biomarkers, such as Gb3 or lyso-Gb3 were considered
to be helpful to determine if the novel mutation is a true
pathogenic mutation [27]. However, several reports indi-
cated that Gb3, and even lysoGb3 might be normal in
certain Fabry patients who had developed significant clin-
ical manifestations with the pathogenic mutations [45,46].
Renal or cardiac biopsy can provide more information to
identify if a novel mutation is a real pathogenic mutation.
In the retrospective single-center direct observational study,
Table 1 The demographic data and clinical manifestations of the Fabry disease patients with IVS4 + 919G > A mutation
Pt Age Sex Comorbidity Histologya α-Gal
Ac
LysoGb3d LVMIe Cr/eGEFf LEg ERTi/Dosej
HC MB MFL Other Diameter Initial biopsy
1 58 M Hyperlipidemia; Hypertension + + + 34.7 ± 4.4 1.35 3.21 57.0 57.0 0.88/94.5 No Not yet/0
2 61 M Hyperlipidemia; Hepatitis B + + + 21.8 ± 3.3 2.75 6.51 66.9 66.9 0.92/88.9 severe Not yet/0
3 75 M Coronary artery disease; Arrhythmia;
Hepatitis C; Cholecystitis
+ + + 31.5 ± 4.0 1.15 6.51 83.0 83.0 1.29/57.7 NAh Not yet/0
4 66 M DM; Hypertension;ESRD s/p renal transplantation;
Cholecystitis; Hyperuricemia
+ + + 30.8 ± 5.6 1.29 7.13 154.9 154.9 1.77/41.1 severe Not yet/0
5 64 M Hypertension; Coronary artery disease;
Hyperlipidemia; Hyperuricemia
+ + + 33.5 ± 8.0 1.32 7.47 128.1 128.1 0.97/82.8 No Not yet/0
6 58 M Hyperlipidemia + + - 24.1 ± 2.4 2.17 9.60 54.5 38.5 1.01/80.6 No 8M/3.80
7 61 M Cubital tunnel syndrome + + + 25.9 ± 2.8 1.54 7.53 52.2 52.2 0.85/97.4 severe 10M/4.11
8 56 M Hypertension; DM; Duodenal ulcer + + - 25.6 ± 7.0 1.39 6.13 74.5 74.8 0.92/90.5 No 10M/4.35
9 66 M Hyperlipidemia; Sick sinus syndrome + + + Fattyb 24.9 ± 3.6 1.15 9.77 136.4 113.9 1.4/53.9 No 1Y5M/7.53
10 52 M Coronary artery disease; Fatty liver + + + Fibrosis 21.1 ± 5.0 0.94 11.27 54.8 61.0 0.86/99.3 No 1Y6M/8.18
11 62 M BPH; Bladder cancer; Osteoarthritis + + - 21.6 ± 4.0 0.79 5.06 50.7 52.8 0.95/85.4 mild 1Y11M/9.76
12 63 M Hyperlipidemia; Arrhythmia s/p pacemaker + + - 23.2 ± 3.4 1.02 13.51 51.2 50.9 1.16/67.6 NAh 2Y9M/14.90
13 58 M Hypertension; Hyperlipidemia + + + 26.2 ± 5.6 1.32 5.44 50.5 41.0 1.15/69.4 mild 2Y10M/15.61
14 58 M Hypertension + + + 24.0 ± 5.4 1.30 8.22 66.5 83.7 1.1470.1 No 2Y11M/16.33
15 66 M Hypertension, Hyperuricemia + + + 24.2 ± 4.1 1.47 14.54 88.2 81.4 0.81/101.3 severe 2Y11M/16.33
16 47 M Hypertension; Arrhythmia + Scanty - 23.1 ± 4.1 0.65 6.16 92.1 74.9 0.8/110.1 severe 4Y3M/44.84
17 58 M Hypertension; DM; BPH + No - 23.6 ± 3.8 0.88 5.19 76.0 71.4 0.84/99.8 severe 4Y3M/36.13
18 60 F Lung adenocarcinoma; Hypertension; Insomnia + + - 24.6 ± 3.4 5.79 2.12 48.9 31.2 0.75/83.8 No 1Y2M/6.51
19 65 F Hypertension + + + 20.5 ± 3.3 9.63 4.24 52.1 37.2 0.62/102.7 No 2Y2M/12.34
20 70 F Hypertension; Major depression + + + 25.8 ± 6.9 6.51 3.67 64.0 54.1 0.67/92.5 mild 2Y9M/14.90
21 62 F Hypertension + + + Fattyb 23.5 ± 3.5 5.17 3.49 53.4 31.1 0.83/74.0 mild 2Y10M/15.35
22 61 F Chronic renal insufficiency; Hyperuricemia + Scanty - 23.5 ± 7.1 4.03 2.60 59.2 49.0 2.98/17.0 No 3Y1M/18.50
DM: diabetes mellitus, BPH: benign prostate hyperplasia, ERT: enzyme replacement therapy, ESRD: end-stage renal disease, MRI: magnetic resonance imaging. aHistology of endomyocardial biopsies: HC: hypertrophic
cardiomyocyte; MB: myelin bodies; MFL: myofibrillolysis; Diameter: minor cardiomyocyte diameter in mean ± SD (μm), and the control: 14.89 ± 2.63 μm; bFatty: fatty infiltration within the myocardium; cα-Gal A: normal
reference ranges: 7.9-16.9 nmol/hr/ml; dLysoGb3: normal reference ranges:<0.5 nM; eLVMI (g/m2.7): left ventricular mass index; fCr/eGFR: Cr(serum creatinine): normal range: 0.5-1.5 mg/dl; eGFR (estimated glomerular
filtration rate): normal range: >60 ml/min/1.73 m2; gLE: late-enhancement by MRI: No: no fibrosis, mild: one segment, severe: more than 2 segment; hNA: not available. The two patients had arrhythmia with implanted




















Figure 2 Histologic examination of the cardiomyopathic patients with IVS4 + 919G > A mutation. (A) Endomyocardial biopsy of patient
no. 4, who had not received ERT, showed a diffuse vacuolization (arrows) attributed to the lysosomal Gb3 storage and hypertrophic change of
cardiomyocytes with hematoxylin and eosin (H&E) staining. These findings were found in most of the enrolled patients. (B) H&E staining of the
endomyocardium showed mild interstitial fibrosis (arrow) only in one patient (no. 10) and showed similar diffuse vacuolization. Toluidine blue
staining of the endomyocardium revealed cytoplasmic granular inclusion (arrow), which is consistent with Gb3 accumulation, in patient no.
4 (C) and patient no. 12 (D) who has received ERT for 2 year and 9 months.
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of later-onset Fabry patients with IVS4 + 919G >A muta-
tion to prove this mutation is a real pathogenic mutation.
Cardiac biopsy of classical Fabry disease patients re-
vealed significant Gb3 accumulation in both endothelium
and cardiomyocytes [47-53]. Furthermore, the degree of
endothelial Gb3 deposition was even used as a scoring
system for monitoring the long-term cardiac therapeutic
outcomes of ERT in classic Fabry disease (Thurberg, B.L.
et al) [54]. In contrast to classical Fabry disease, cardiac bi-
opsy of the later-onset patients revealed that Gb3 accumu-
lation was confined to the myocardium and did not
involve endothelial cells [55]. Other reports have also
showed no endothelial Gb3 accumulation in later-onset
Fabry disease [56-58]. Therefore, no endothelial Gb3 de-
position is expected in later-onset Fabry patients. The car-
diac biopsies of our patients showed significant Gb3accumulation in their cardiomyocytes but not in endothe-
lial cells. It could indicate that IVS4 + 919G >A mutation
is a true later-onset Fabry mutation.
Interestingly, a high frequency of hypertension (12 of
22; 54%) and hyperlipidemia (7 of 22; 32%) were noted
among these cardiomyopathic patients with the IVS4 +
919G > A mutation. In this study, we did not check
other genetic causes of hypertrophic cardiomyopathy.
Actually, the exact causal relationship of these factors
with hypertrophic cardiomyopathy in our patients has
not established. Because most of our patients did not
have significant renal impairment, the hypertension was
not likely caused by Fabry renopathy. Several studies
have indicated that in addition to renal impairment,
hypertension could be caused by the imbalance of the
autonomic nervous system in patients with Fabry disease
[59]. Further studies are required to clarify the relationship
Figure 3 Scanty or little Gb3 accumulation of the two patients who had received ERT. The figures showed the endomyocardial histologic
examination of the patients (No. 16 and 17) who had received ERT for more than 3 years. Patient No. 17 showed no Gb3 accumulation with H&E
staining (A), toluidine blue staining (B), and electron microscope exam (C). Patient No. 16 still showed scanty vacuolization (arrow) with H&E
staining (D), Gb3 accumulation (arrow) with Toluidine blue staining (E), and myelin bodies (arrow) in electron microscope exam (F).
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ance in these patients. Furthermore, hypertension might
be a predisposing factor to the development of hyper-
trophic cardiomyopathy for these later-onset Fabry disease
patients, especially for the milder Fabry patients. The
finding that four out of our five (80%) female patients
had significant hypertension supports this finding. In
addition, several IVS4 + 919G > A patients in our studies
were found to be hypertensive. However, due to the small
sample size in our study, we cannot make a definite con-
clusion regarding the relationship between hypertrophic
cardiomyopathy and hypertension, more data will need to
be collected and analyzed to clarify this point. Regarding
predisposing factors for hypertrophic cardiomyopathy in
later-onset Fabry patients, a recent important study, re-
ported by Desnick et al. [60], revealed that as many as
20% of male and 25% of females with later onset Fabry
mutations and hypertrophic cardiomyopathy concur-
rently have a pathogenic or likely pathogenic mutation
of the HCM causing gene. Therefore, in addition to Gb3
accumulation, there should be some predisposing factors
contributing to the pathogenesis of later-onset Fabry
cardiomyopathy.
Regarding hyperlipidemia in Fabry patients, circulating
Gb3 has been proved to be primary transported by LDL
and HDL lipoproteins (approximately 60% and 30%respectively) [61]. Furthermore, hyperlipidemia was cor-
related with Fabry disease [62] and selective LDL-
apheresis was shown to be an effective treatment in a
Fabry patient with recurrent strokes [63]. However, the
causal relationship between hyperlipidemia and hyper-
trophic cardiomyopathy of later-onset Fabry patients still
needs to be clarified.
Interestingly, only scanty Gb3 accumulation could be
found in the cardiomyocytes of our three patients who
had received the longest period of ERT. This finding is
quite different from several previous studies that showed
the histological clearance of Gb3 accumulation from car-
diomyocytes is usually poor [38,49,54,64]. Does this fin-
ding indicate that a longer duration of ERT still has
efficacy for Gb3 clearance from cardiomyocytes of later-
onset Fabry patients? However, without pre-ERT biopsies,
it is impossible to claim ERT was able to clear Gb3 accu-
mulation from the cardiomyocytes of these three patients.
More cardiac biopsy data with pre-ERT and post-ERT
should be collected to clarify this point.
Recent studies revealed that gadolinium-contrast car-
diac MRI is a good method to assess myocardial fibrosis
in Fabry disease [34,65-67]. In patients without fibrosis,
ERT resulted in a significant reduction in left ventricular
mass and improvement of myocardial function. In con-
trast, patients with mild or severe fibrosis showed a minor
Figure 4 Electron microscopic examination of the patients with left ventricular hypertrophy and IVS4 + 919G > A mutation. Electron
microscopic findings of the cardiomyocytes from patient no. 20 showed abundant membrane-bound lamellar myelin bodies (“zebra” or “onion-
skin” appearance) (arrow) in this figure (A). The myelin bodies (arrow) were also found in most of the patients who received biopsy in this study.
Further examples were showed in figure (B) (patient no. 8) and (C) (patient no. 2). Focal loss of myofilament (myofibrillolysis) (arrow), which may
be attributed from glycosphinogolipid accumulation and was found in 14 out of 22 case, is presented in figure (D) (patient no. 4). No Gb3
accumulation was found in the capillary endothelium of all these patients. The endothelium (the arrow) were presented in figure (E) (patient No. 2)
and (F) (patient No. 3). The scale bars = 2 μm.
Figure 5 The cardiomyocyte diameter of the patient no. 1 with
H&E staining. Diameters (minor axis) of the cardiomyocyte in
transverse sections were obtained by measuring the shortest
perpendicular measurement line (dark line), which was placed at the
level of nucleus. Five cardiomyocytes were measured and their
diameters were also presented in beside the dark line (yellow).
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http://www.ojrd.com/content/9/1/96reduction in left ventricular hypertrophy and no improve-
ment in myocardial function. In this study, one patient
was found to have significant interstitial fibrosis among
his cardiomyocytes by H&E staining of endomyocardial
biopsy. However, no significant fibrosis was observed in his
heart with late-enhancement technique by gadolinium-
contrast cardiac MRI examination. On the other hand, 6
out of the 20 patients received gadolinium-contrast cardiac
MRI examination in this study were found to have severe
fibrosis (Table 1), but none of them were found to have any
significant cardiac fibrosis in their endomyocardial biopsies.
This finding indicates that the histological fibrosis of inter-
ventricular septum from right ventricular endomyocardial
biopsy does not reflect the severity of the fibrosis of the
whole heart; most of the fibrosis that significantly affect
heart function is usually located in the left ventricular area
in Fabry disease.
In this study, we analyzed the pathologic appearance of
cardiomyocytes by endomyocardial biopsies in 22 atypical
later-onset Fabry disease patients with the Chinese
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http://www.ojrd.com/content/9/1/96mutation (IVS4 + 919G > A). These data suggest that
IVS4 + 919G > A is a real pathogenic mutation with typ-
ical Gb3 accumulation and hypertrophic changes in car-
diomyocytes. No endothelial Gb3 accumulation was
found in cardiac biopsies is consistent with the cardiac
pathologic findings of later-onset Fabry disease.
Conclusions
Fabry disease is a rare lysosomal disorder resulting from a
genetic deficiency of α-Gal A. The present study used
endomyocardial biopsies to confirm that the Chinese
Fabry mutation (IVS4 + 919G > A) is a real pathogenic
mutation.
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